Zolbetuximab in the treatment of advanced gastric and gastroesophageal junction cancer: a systematic review
IntroductionAdvanced gastric and gastroesophageal junction (G/GEJ) adenocarcinomas are characterized by an aggressive course and a very poor prognosis. Due to the limited benefit of immunotherapy in patients with HER2-negative tumors, new therapeutic targets are sought. Zolbetuximab is a chimeric mo...
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2026-07-01
|
| Collection: | Frontiers in Immunology |
| Sujets: | |
| Accès en ligne: | https://www.frontiersin.org/articles/10.3389/fimmu.2026.1870010/full |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|